Home › Cases › Hypertensive Acute Heart Failure
Acute Heart Failure
Hypertensive Acute Heart Failure
6 questions
Question 1 · Hypertensive AHF
Correct answer: Hypertensive acute heart failure — dramatic flash pulmonary oedema secondary to hypertensive emergency (vasoconstriction, afterload surge)
Why
Hypertensive AHF (flash pulmonary oedema): acute increase in afterload from severe hypertension → LV cannot eject against resistance → LVEDP rises rapidly → acute pulmonary oedema. Often preserved EF (systolic function usually maintained). Responds rapidly to vasodilators. Different from chronic decompensated HF.
Key point
Hypertensive AHF: high BP → increased afterload → acute pulmonary oedema. Usually preserved EF. Vasodilators key.
Question 2 · Treatment priority
Correct answer: Vasodilators first (IV GTN infusion) — reduces afterload rapidly, relieves pulmonary oedema. Add CPAP. Furosemide secondary (these patients often not fluid overloaded)
Why
Hypertensive AHF treatment: vasodilators are the priority (IV GTN 1–10mg/hr) — reduces SVR and preload simultaneously. IV GTN most rapid and titratable. CPAP immediately (improves oxygenation and reduces afterload). Furosemide: useful but these patients may not be hypervolaemic — the oedema is from redistribution, not total fluid excess.
Key point
Hypertensive AHF: IV GTN infusion (vasodilator) + CPAP first. These patients often NOT hypervolaemic. Furosemide secondary.
Question 3 · CPAP in AHF
Correct answer: CPAP: positive airway pressure reduces preload and afterload (reduces venous return and LV transmural pressure), recruits alveoli, reduces work of breathing, improves oxygenation
Why
CPAP reduces preload (↓venous return) and LV afterload (↓transmural pressure), recruits alveoli and ↓work of breathing. 3CPO showed faster improvement in breathlessness and physiology, but no demonstrated reduction in intubation or mortality. Wider evidence supports NIV to reduce intubation risk in selected patients.
Key point
CPAP in AHF: reduces preload + afterload + work of breathing + recruits alveoli. Reduces intubation rate. Start early.
Question 4 · IV versus oral furosemide
Correct answer: Consider twice her usual daily dose IV: 80mg oral daily → 160mg IV by slow infusion, with senior review and response monitoring
Why
Oral furosemide absorption is variable and may worsen with gut oedema. ESC 2026 considers an initial IV dose twice the usual outpatient oral dose: here 80mg/day →160mg IV, adjusted for congestion, BP and renal function. Give by slow infusion, checking the product rate limit (usually ≤4mg/min). DOSE found greater decongestion with higher dosing but more transient renal deterioration; reassess urine output and U&E.
Key point
80mg oral daily → consider 160mg IV slowly, with senior input. Reassess congestion, BP, urine output and U&E; this is not a routine maintenance conversion.
Question 5 · Discharge triggers
Correct answer: Clinically stable, oxygenation on room air, oral diuretics tolerated, BP controlled, daily weight stable, no evidence of congestion
Why
AHF discharge criteria: euvolaemic (weight stable, no oedema), off IV diuretics, ambulatory and able to cope at home, oral diuretic dose determined, BP controlled, stable SpO2 on room air (usually 94–98%; 88–92% if at risk of hypercapnic respiratory failure, or documented baseline target). BNP not required to normalise before discharge. Weight at discharge recorded for monitoring. Specialist HF-team review within 2 weeks, with GP handover.
Key point
AHF discharge: euvolaemic, off IV diuretics, stable oxygenation at the appropriate target and BP controlled. Record weight; specialist HF team within 2 weeks, with GP handover.
Question 6 · ACEI and AHF
Correct answer: ACEi or sacubitril-valsartan (ARNI), beta-blocker, mineralocorticoid antagonist, SGLT2 inhibitor — the 4 pillars of HFrEF treatment. Start low dose before discharge
Why
HFrEF medical therapy: 4 pillars —
- ACEi/ARB or ARNI (sacubitril-valsartan)
- Beta-blocker
- MRA (spironolactone/eplerenone)
- SGLT2 inhibitor
Each independently reduces mortality. PIONEER-HF trial: start sacubitril-valsartan in hospital if haemodynamically stable.
Key point
HFrEF 4 pillars: ACEi/ARNI + beta-blocker + MRA + SGLT2i. Start before discharge if stable. All reduce mortality.
Case complete
Practice on this page does not update your app progress. Open the browser app if you want its learning tools and progress record.